Research programme: oncolytic viruses - Geron

Drug Profile

Research programme: oncolytic viruses - Geron

Alternative Names: Ad2/phTERT-E1A; OV1060

Latest Information Update: 17 Jul 2007

Price : $50

At a glance

  • Originator Geron Corporation
  • Class Oncolytic viruses
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jul 2007 Preclinical development is ongoing
  • 14 Jun 2005 This compound is still in active development
  • 24 Mar 2003 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top